News
Vail Health launches study investigating how to expand antidepressant effects of psilocybin
_reg.jpeg)
All OPTIMIZE study participants receive psilocybin, which has been proven to positively impact patients with depression
Psilocybin, the active psychedelic ingredient in magic mushrooms, has been proven to impact patients with depression positively. Vail Health’s OPTIMIZE study, which will administer doses of psilocybin to all 140 participants, aims to investigate how to predict and enhance this effect.“In our (psilocybin) studies, only half the people that get a high dose are really feeling completely fine six weeks later,” said Charles Raison, director of Vail Health’s Behavioral Health Innovation Center. “We want to try to see, can we get 70 percent of people there, 80 percent of people?”
The OPTIMIZE study examines the impact of noninvasive vagus nerve stimulation on patients with depression who have received a strong dose of psilocybin.
Read the full article >
More News
-
New!
More
Sarah Drew Honored as Recipient of Vail Health Elevate Award
Sarah Drew, MSN, FNP-C, ENP-C, Senior Director of Emergency and Trauma Services at Vail Health, has been named the recipient of the Vail Health Elevate Award.
-
New!
More
First Baby of 2026
It's a boy! Vail Health Hospital welcomed the first baby born in 2026 on January 5 at 7:48 p.m.
-
More
Screening Secrets: What Every Man Should Know About Prostate Cancer Screening
Prostate cancer is the most common type of non-skin related cancer in men, and it is the second leading cause of cancer-related deaths in men within the United States, behind lung cancer. Fortunately, if caught early, prostate cancer remains highly treatable and curable with minimally invasive procedures.